Key facts
- Equilibrium Labs’s last known valuation is $25.7M (Jun 2025).
- It has raised $5.5M; the latest was Later Stage VC ($5.5M) in Jun 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Equilibrium Labs
- ·The full record, as it builds
Funding rounds
No funding rounds for Equilibrium Labs are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Equilibrium Labs
Manufacturer of nutraceutical detoxification products intended to help people improve their health while enjoying life to the full. The company develops natural liver health remedies combining Eastern herbal medicine with Western technology, which helps in stimulating metabolism, protects the liver from alcohol and other toxins, aiding the liver's ability to regenerate, enabling patients to take better care of themselves and treat the disease properly.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2013
- Employees
- 17
- Website
- equilibriumlabs.com/
- Ownership
- Privately Held (backing)
Equilibrium Labs doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Equilibrium Labs shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Equilibrium Labs in its N-PORT filings yet. We sweep new filings monthly.